Tafinlar (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the Tafinlar drug offered from Novartis Pharmaceuticals Corporation. This Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Cytochrome P450 2C8 Inducers [MoA],Cytochrome P450 2C9 Inducers [MoA],Cytochrome P450 2C19 Inducers [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Organic Anion Transporter 1 Inhibitors [MoA],Organic Anion Transporter 3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | dabrafenib |
| SUBSTANCE NAME: | DABRAFENIB MESYLATE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Cytochrome P450 2C8 Inducers [MoA],Cytochrome P450 2C9 Inducers [MoA],Cytochrome P450 2C19 Inducers [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Organic Anion Transporter 1 Inhibitors [MoA],Organic Anion Transporter 3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | CAPSULE |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2016-04-01 |
| END MARKETING DATE: | 0000-00-00 |
Tafinlar HUMAN PRESCRIPTION DRUG Details:
| Item Description | Tafinlar from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 75(mg/1) |
| START MARKETING DATE: | 2016-04-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0078-0681_cab88fd1-802f-4602-8c6f-f4d20b537662 |
| PRODUCT NDC: | 0078-0681 |
| APPLICATION NUMBER: | NDA202806 |
Other DABRAFENIB MESYLATE Pharmaceutical Manufacturers / Labelers:
